UK Vows £100 Million for Biosecurity Lab With OpenAI, Anthropic
THE SO WHAT
A £100M AI Biosecurity Lab with OpenAI, Anthropic, and Google DeepMind formalizes bio-risk as a first-class AI policy and research domain. Healthcare, biotech, and cloud vendors touching biological data should expect more pre-clearance, audits, and specialized guardrails baked into deals and APIs.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging Tech32 TB RAM for your GPUs: Marvell shows revolutionary Photonic Fabric Memory Module that uses light to link up to 16 GPUs and slash CAPEX — but Nvidia won't stick around doing nothing
Optically pooled 32 TB memory across up to 16 GPUs turns the GPU from a memory controller into a pure compute engine—if it ships on Marvell’s 2027 timeline, cluster design and capex math change. Infra teams planning multi-year buildouts should at least scenario-plan around disaggregated, photonic memory as a future option.
Deep & Emerging TechAI Ushers in New Era of Cybersecurity Needs
The White House treating PHP flaws as a national infrastructure risk is a reminder that AI-era security failures will often start in old code, not new models. If your stack still leans on legacy languages and libraries, your AI roadmap is only as credible as your software supply-chain hygiene.
Deep & Emerging TechNATO jammers will block out GPS for miles around — and they could be the secret weapon in the next big conflict
NATO training with large-scale GPS jamming is a blunt reminder that positioning and timing are wartime targets, not utilities. Any autonomy, logistics, or telecom system that quietly assumes GPS reliability needs a resilience review now, not after a disruption.
Deep & Emerging TechThe real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
For oncology operators, the question isn’t just whether Moderna’s cancer vaccine can match Keytruda in the short term—it’s whether it can durably suppress recurrence over years, which changes trial design, follow-up infrastructure, and payer negotiations. Early data will drive headlines, but long-term outcomes will drive formulary and care-pathway rewrites.